Melanoma and non-small cell lung cancer (NSCLC) display exceptionally high mutational burdens. Hence, immune targeting in these cancers has primarily focused on tumor antigens (TAs) predicted to derive from nonsynonymous mutations. Using comprehensive proteogenomic analyses, we identified 589 TAs in cutaneous melanoma (n = 505) and NSCLC (n = 90). Of these, only 1% were derived from mutated sequences, which was explained by a low RNA expression of most nonsynonymous mutations and their localization outside genomic regions proficient for major histocompatibility complex (MHC) class I-associated peptide generation. By contrast, 99% of TAs originated from unmutated genomic sequences specific to cancer (aberrantly expressed tumor-specific antigens (aeTSAs), n = 220), overexpressed in cancer (tumor-associated antigens (TAAs), n = 165) or specific to the cell lineage of origin (lineage-specific antigens (LSAs), n = 198). Expression of aeTSAs was epigenetically regulated, and most were encoded by noncanonical genomic sequences. aeTSAs were shared among tumor samples, were immunogenic and could contribute to the response to immune checkpoint blockade observed in previous studies, supporting their immune targeting across cancers.
MHC-I-associated peptides (MAPs) derive from selective yet highly diverse genomic regions, including allegedly non-protein-coding sequences, such as endogenous retroelements (EREs). Quantifying canonical (exonic) and non-canonical MAPs-encoding RNA expression in malignant and benign cells is critical for identifying tumor antigens (TAs) but represents a challenge for immunologists. We present BamQuery, a computational tool attributing an exhaustive RNA expression to MAPs of any origin (exon, intron, UTR, intergenic) from bulk and single-cell RNA-sequencing data. We show that non-canonical MAPs (including TAs) can derive from multiple different genomic regions (up to 35,343 for EREs), abundantly expressed in normal tissues. We also show that supposedly tumor-specific mutated MAPs, viral MAPs, and MAPs derived from proteasomal splicing can arise from different unmutated non-canonical genomic regions. The genome-wide approach of BamQuery allows comprehensive mapping of all MAPs in healthy and cancer tissues. BamQuery can also help predict MAP immunogenicity and identify safe and actionable TAs.
Cutaneous melanoma exhibits strong responses to immunotherapy, yet the system-level mechanisms linking mutational burden, genomic alterations, antigen landscapes, post-transcriptional and post-translational regulation, and immune outcomes remain incompletely defined. We profiled 183 cutaneous melanomas using 13 omic layers, including immunopeptidomics, metabolomics, protein ubiquitylation and glycosylation, to construct a holistic view of tumor immunogenicity. Mass spectrometry-based HLA-I immunopeptidomics revealed correlation between tumor antigens and CD8+ T-cell infiltration. Metabolomics revealed distinct ether-linked lipids and mitochondrial metabolic profiles between primary and metastatic tumors. Ubiquitylomics uncovered a subset of tumors associated with worse survival, characterized by high ubiquitylation of the IFN signaling pathway and ubiquitylation-dependent activation of AKT1. Glycoproteomic analyses identified GPNMB glycosylation as a key feature associated with sex-specific survival, linking this signal to a lysosome-associated program and suggesting potential sex-dependent differences in immunotherapy response. This multi-omic atlas of cutaneous melanoma illuminates mechanisms of immune evasion, informing treatment-relevant patient stratification in melanoma care.